Embecta Corp.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Devdatt Kurdikar
- Full Time Employees
- 2,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 300 Kimball Drive Parsippany NJ United States of America 07054
- IPO Date
- Mar 22, 2022
- CIK
- 0001872789
- Website
- embecta.com
- Similar Companies
- Business
- Embecta Corp. (Nasdaq: EMBC), a global medical device company focused on diabetes care solutions, designs, manufactures and markets insulin delivery products including pen needles, syringes, safety injection devices; digital applications such as the BD Diabetes Care app for patient management; and innovative technologies like patch pump systems, primarily sold to wholesalers, distributors, pharmacies and healthcare providers serving people living with diabetes in over 100 countries. Founded in 1924 and headquartered in Parsippany, New Jersey, the company operates manufacturing facilities in the United States, Ireland and China while maintaining nearly 100 years of expertise spun off from Becton Dickinson in April 2022. Embecta recently strengthened its leadership through a long-range financial plan for fiscal 2025-2028 targeting flat constant currency revenue growth, adjusted operating margins of 28-30% and $600 million in cumulative free cash flow; expanded partnerships with over 30 generic GLP-1 companies for pen needle co-packaging and supply including purchase orders and regulatory submissions; committed to expanded humanitarian efforts with Direct Relief through 2026 for pen needle and syringe access following a July 2025 Texas grant; and reported fiscal 2025 fourth quarter results with Q3 revenue near $296 million amid ongoing transition to growth and diversification including GLP-1 opportunities and debt reduction.
embecta to Participate in Investor Events
EMBC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Embecta Corp.
EMBC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Embecta Corp.
Bragar Eagel & Squire, P.C. is Investigating Embecta Corp. on Behalf of Embecta Stockholders and Encourages Investors to Contact the Firm
EMBC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Embecta Corp.
EMBC INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Embecta Corp.
Levi & Korsinsky Investigating Whether Embecta Corp. (EMBC) Misled Investors - Securities Law Violations Possible
EMBC SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Embecta Corp. (EMBC) Securities Fraud Investigation - Levi & Korsinsky
Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification
embecta Completes Acquisition of Owen Mumford Holdings Limited
Levi & Korsinsky Announces Investigation of Securities Claims Against Embecta Corp. (EMBC)
Embecta Corp. (EMBC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
EMBC Investor Alert: Levi & Korsinsky Investigates Embecta Corp. (EMBC) for Potential Securities Fraud
embecta to Participate at the 2026 BofA Securities Global Health Care Conference
EMBC ACTIVE INVESTIGATION: Lost Money on Embecta Corp.? Contact Levi & Korsinsky Now
Embecta: A Sharp Decline On Q2 Earnings, But There's Still No Opportunity
Embecta Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Why Embecta Stock Plummeted Today
Embecta Corp. (EMBC) Q2 2026 Earnings Call Transcript